HLS Therapeutics Inc T.HLS

Alternate Symbol(s): HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.

TSX:HLS - Post by User

HLS Therapeutics Inc

Bullboard Posts

Comment by LTOWNERon Apr 04, 2012 12:04pm

177 Views

Post# 19758323

RE: RE: RE: RE: RE: RE: Ford March Sales up 5%

"as the contract approaches expiration" - the current contract with Ford does not expire for 2 years - June 2014. But gcoutts is right, AM is unlikely to be replaced by another supplier due to barriers to entry. It costs $ 6-7 million to set up for new designs plus AM is located 15 to 20 minutes from Ford in order to deliver parts 'on demand'. In addition the parts AM supplies for the Ford contract require a far more complicated sub assembly than what AM used to build for GM; AM cannot easily be replaced although Ford could possibly decide to do the sub-assembly in house, some time in the future.

Bullboard Posts

Corus reports Q1 profit drop in the face of falling revenue